In the late 1960s, researchers at the Weizmann Institute of Science, including Professors Michael Sela and Ruth Arnon and Dr.

A 2016 phase 2 trial found that estriol plus glatiramer acetate (the drug in Copaxone and Glatopa) reduced relapse rates in women with MS and was well tolerated for the two years of the study. This ...

The Scientist explored the work of a researcher who had an unexpected finding while developing a novel anti-tau therapy.

A U.S. court of appeals has reportedly ruled that a whistleblower case against Novartis (NVS) over alleged kickbacks ...

A U.S. appeals court on Friday revived a whistleblower lawsuit accusing Swiss drugmaker Novartis of paying illegal kickbacks ...

Ann Lewandowski knows all about pharmacy benefit managers, or PBMs, the companies that shape the U.S. drug market. Her job, ...

MP-1032 is under clinical development by MetrioPharm and currently in Phase I for Multiple Sclerosis. According to GlobalData, Phase I drugs for Multiple Sclerosis have a 72% phase transition success ...

As criticism of pharmacy benefit managers heats up, fear of lawsuits is driving some big employers to drop the “Big Three” ...

Tolebrutinib is under clinical development by Sanofi and currently in Phase III for Secondary Progressive Multiple Sclerosis (SPMS).

Recent health developments include a new injectable cancer drug by Bristol Myers Squibb, a revived lawsuit against Novartis ...

Recent health news includes the FDA's approval of an injectable version of Opdivo, a revived lawsuit against Novartis for ...